ES2098920T3 - PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF NICOTINE DEPENDENCE. - Google Patents

PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF NICOTINE DEPENDENCE.

Info

Publication number
ES2098920T3
ES2098920T3 ES94905025T ES94905025T ES2098920T3 ES 2098920 T3 ES2098920 T3 ES 2098920T3 ES 94905025 T ES94905025 T ES 94905025T ES 94905025 T ES94905025 T ES 94905025T ES 2098920 T3 ES2098920 T3 ES 2098920T3
Authority
ES
Spain
Prior art keywords
pct
treatment
pharmaceutical formulations
nicotine dependence
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94905025T
Other languages
Spanish (es)
Inventor
Joachim Arnold Moormann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
HF Arzneimittelforschung GmbH and Co KG
Original Assignee
LTS Lohmann Therapie Systeme AG
HF Arzneimittelforschung GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG, HF Arzneimittelforschung GmbH and Co KG filed Critical LTS Lohmann Therapie Systeme AG
Application granted granted Critical
Publication of ES2098920T3 publication Critical patent/ES2098920T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PCT No. PCT/EP94/00055 Sec. 371 Date Oct. 30, 1995 Sec. 102(e) Date Oct. 30, 1995 PCT Filed Jan. 10, 1994 PCT Pub. No. WO94/16708 PCT Pub. Date Aug. 4, 1994The present invention relates to the use of galanthamine and the pharmaceutically acceptable acid addition salts thereof for the treatment of nicotine dependence. The active substances are released from pharmaceutical formulations, e.g., orally, transdermally, or otherwise parenterally in a continuous and controlled manner.
ES94905025T 1993-01-23 1994-01-10 PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF NICOTINE DEPENDENCE. Expired - Lifetime ES2098920T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4301782A DE4301782C1 (en) 1993-01-23 1993-01-23 Use of galanthamine to treat nicotine addiction

Publications (1)

Publication Number Publication Date
ES2098920T3 true ES2098920T3 (en) 1997-05-01

Family

ID=6478780

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94905025T Expired - Lifetime ES2098920T3 (en) 1993-01-23 1994-01-10 PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF NICOTINE DEPENDENCE.

Country Status (23)

Country Link
US (1) US5643905A (en)
EP (1) EP0680326B1 (en)
JP (1) JP3511074B2 (en)
KR (1) KR100301547B1 (en)
AT (1) ATE146677T1 (en)
AU (1) AU685075B2 (en)
CZ (1) CZ284605B6 (en)
DE (2) DE4301782C1 (en)
DK (1) DK0680326T3 (en)
ES (1) ES2098920T3 (en)
GR (1) GR3022862T3 (en)
HR (1) HRP940029B1 (en)
HU (1) HU221159B1 (en)
IL (1) IL108234A (en)
MY (1) MY111260A (en)
NO (1) NO306894B1 (en)
NZ (1) NZ259858A (en)
PL (1) PL174812B1 (en)
SI (1) SI9400028A (en)
SK (1) SK282247B6 (en)
WO (1) WO1994016708A1 (en)
YU (1) YU48559B (en)
ZA (1) ZA94413B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509663A1 (en) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Process for the isolation of galanthamine
AT402691B (en) * 1996-01-26 1997-07-25 Sanochemia Ltd USE OF GALANTHAMINE FOR PRODUCING MEDICINAL PRODUCTS FOR TREATING TRISOMY 21 OR RELATED TRISOMY SYNDROME
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
WO2000030446A1 (en) * 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
CZ301658B6 (en) 1998-12-24 2010-05-19 Janssen Pharmaceutica N. V. Pharmaceutical compositions with controlled release of galanthamine
DE19906978B4 (en) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmaceutical composition containing deoxypeganine for the treatment of drug dependence
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
CA2393301A1 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
DE10018834A1 (en) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermal or transmucosal pharmaceutical dosage form for treatment of nicotine dependence or smoking withdrawal contains nicotine compound or substitute and CNS active compound
DE10119862A1 (en) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Use of galanthamine for the treatment of symptoms of the central nervous system due to intoxications with psychotropic substances
SE521512C2 (en) 2001-06-25 2003-11-11 Niconovum Ab Device for administering a substance to the front of an individual's oral cavity
DE10134038A1 (en) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Active ingredient combination for drug therapy of nicotine addiction
DE10235556A1 (en) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medicament for treating substance cravings, especially alcohol and/or tobacco abuse, comprising separate dosage forms for continuous release of nicotinic receptor modulator and rapid delivery of galanthamine
DE60313216T2 (en) 2002-12-20 2008-01-03 Niconovum Ab CHEMICALLY AND PHYSICALLY STABLE PARTICLE MATERIAL CONTAINING NICOTIN AND MICROCRYSTALLINE CELLULOSE
JP2006519225A (en) * 2003-02-27 2006-08-24 社団法人芝蘭会 Pharmaceutical composition for treating addiction
BG65658B1 (en) * 2003-11-13 2009-05-29 "Софарма" Ад Galantamin-based combined medicamentous product
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
US20050142193A1 (en) * 2003-12-31 2005-06-30 Lijuan Tang Galantamine formulations
WO2005115471A2 (en) * 2004-05-27 2005-12-08 Neurocure Ltd. Methods and compositions for treatment of nicotine dependence and dementias
JP5694645B2 (en) 2006-03-16 2015-04-01 ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ Improved snuff composition
US8952038B2 (en) 2010-03-26 2015-02-10 Philip Morris Usa Inc. Inhibition of undesired sensory effects by the compound camphor
UA112411C2 (en) 2010-03-26 2016-09-12 Філіп Морріс Продактс С.А. PREVENTION OF IRRITATION OF RECEPTORS IN CONSUMPTION OF SMOKING TOBACCO PRODUCTS
CN101829068A (en) * 2010-05-06 2010-09-15 徐州市光合生物营养品有限公司 Water soluble medicament sustained-release tablets and preparation method thereof
BG66818B1 (en) 2013-03-07 2019-01-31 Berbee Beheer B. V. Composition of hippeastrum papilio extract for the production of medicines and nutritional supplements
US10335378B2 (en) 2013-03-15 2019-07-02 Altria Client Services Llc Inhibition of central nervous system effects from smoking and sensory effects from smoking
BG67408B1 (en) 2019-04-12 2022-01-17 Софарма Ад Oral drug composition with plant alkaloid for treatment of addictions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3760805A (en) * 1971-01-13 1973-09-25 Alza Corp Osmotic dispenser with collapsible supply container
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4137300A (en) * 1976-08-20 1979-01-30 Ciba-Geigy Corporation Sustained action dosage forms
DE3315272C2 (en) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmaceutical product and process for its manufacture
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE3629304A1 (en) * 1986-08-28 1988-03-24 Lohmann Gmbh & Co Kg TRANSDERMAL THERAPEUTIC SYSTEM, ITS USE AND METHOD FOR THE PRODUCTION THEREOF
DE3843239C1 (en) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE4010079A1 (en) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF ALCOHOLISM
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
ES2134215T3 (en) * 1991-05-14 1999-10-01 Ernir Snorrason TREATMENT OF FATIGUE SYNDROMES WITH CHOLINESTERASE INHIBITORS.

Also Published As

Publication number Publication date
NO952906D0 (en) 1995-07-21
AU5881894A (en) 1994-08-15
DK0680326T3 (en) 1997-06-23
EP0680326B1 (en) 1996-12-27
NO306894B1 (en) 2000-01-10
NO952906L (en) 1995-07-21
JP3511074B2 (en) 2004-03-29
EP0680326A1 (en) 1995-11-08
DE4301782C1 (en) 1994-08-25
IL108234A (en) 1996-10-31
YU48559B (en) 1998-11-05
KR100301547B1 (en) 2001-10-22
HRP940029B1 (en) 2000-06-30
WO1994016708A1 (en) 1994-08-04
SK89095A3 (en) 1996-05-08
PL174812B1 (en) 1998-09-30
SK282247B6 (en) 2001-12-03
ATE146677T1 (en) 1997-01-15
HU9501964D0 (en) 1995-09-28
PL309604A1 (en) 1995-10-30
IL108234A0 (en) 1994-04-12
US5643905A (en) 1997-07-01
HU221159B1 (en) 2002-08-28
HRP940029A2 (en) 1997-06-30
CZ284605B6 (en) 1999-01-13
AU685075B2 (en) 1998-01-15
ZA94413B (en) 1994-09-09
MY111260A (en) 1999-10-30
NZ259858A (en) 1997-03-24
GR3022862T3 (en) 1997-06-30
KR960700061A (en) 1996-01-19
YU2494A (en) 1997-01-08
DE59401401D1 (en) 1997-02-06
HUT72670A (en) 1996-05-28
CZ184395A3 (en) 1996-02-14
JPH08505633A (en) 1996-06-18
SI9400028A (en) 1994-09-30

Similar Documents

Publication Publication Date Title
ES2098920T3 (en) PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF NICOTINE DEPENDENCE.
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
ES2156028T3 (en) Compositions containing tetrahydrolipstatin
ES2136723T3 (en) USE OF N-ARYL-METHYLENE-ETHYL-DIAMINE-TRIACETATES, N-ARYL-METHYLENE-IMINO-DIACETATES OR N, N'-DIARYL-METHYLENE-DIAMINE-ACETATES AGAINST OXIDIZING STRESS.
BR9407748A (en) Pharmaceutical formulation: process for preparing the same and process for the prevention and / or treatment of neurodegeneration or for obtaining an anti-convulsive effect or sedation in a patient
ES2177642T3 (en) USE OF CERTAIN DERIVATIVES OF METHANOPHYPHOSPHONIC ACID TO PREVENT DETACHMENT AND MIGRATION OF PROTESIS.
ATE213633T1 (en) MEDICINAL CONTAINING LAMOTRIGINE
MY124465A (en) Reduction of infarct volume using citicoline
BR9608392A (en) Multiparticulate controlled-release preparation and tablet dosage form.
GEP20043377B (en) Pharmaceutical Complex
ATE234096T1 (en) PHARMACEUTICAL COMPOSITION FOR SYSTEMIC TRANSDERMAL ADMINISTRATION CONTAINING THE ACTIVE INGREDIENT MORPHINE-6-GLUCURONIDE
DE60306503D1 (en) STATIN THERAPY FOR IMPROVING THE MAINTENANCE OF COGNITIVE FUNCTION
PE20011042A1 (en) USE OF GLUTAMINE FOR THE PREVENTION OF LATE ONSET DIARRHEA INDUCED BY IRINOTECAN

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 680326

Country of ref document: ES